Table 5.
Effect of malvidin treatment in the polypharmacy-induced duodenal ulcer model.
| Experimental Model | Treatment (p.o.) |
Dose (mg/kg) |
MPO (Unit of MPO/g) |
GSH (nmol/g) |
CAT (Unit of CAT/g) |
SOD (Unit of SOD/g) |
IL-10 (pg/mL) |
IL-6 (pg/mL) |
IL-1β (pg/mL) |
TNF-α (pg/mL) |
|---|---|---|---|---|---|---|---|---|---|---|
| Polypharmacy-induced duodenal ulcer | Vehicle | - | 95.3 ± 19.4 | 734.9 ± 74.2 | 45.6 ± 6.0 | 12.3 ± 1.4 | 1791.0 ± 350.0 | 495.8 ± 167.7 | 6377.0 ± 1128.0 | 1433.0 ± 447.8 |
| Malvidin | 5 | 36.9 ± 8.0 ** | 765.0 ± 66.4 | 84.8 ± 6.6 ** | 9.7 ± 2.0 | 1801.0 ± 326.1 | 193.2 ± 40.8 * | 6056.0 ± 861.2 | 565.3 ± 91.1 * | |
| Naïve | - | 27.3 ± 9.4 ** | 910.7 ± 50.6 | 84.0 ± 4.1 ** | 16.7 ± 0.5 | 1799.0 ± 494.7 | 223.4 ± 33.4 | 5595.0 ± 674.0 | 649.6 ± 112.6 |
The results show the effect of vehicle and malvidin (5 mg/kg) in the activity of mieloperoxidase (MPO), catalase (CAT), superoxide dismutase (SOD), levels of reduced glutathione (GSH) and cytokines concentration in the small intestine from animals submitted to duodenal ulcer induced by polypharmacy. Data are presented as mean ± S.E.M. ANOVA followed by Dunnett′s test. * p < 0.05 and ** p < 0.01 represents difference in relation to control group treated with vehicle.